logo
Twitter
Discord
Email
logo
Agilent Technologies, Inc.

Agilent Technologies, Inc.

NYSE•A
CEO: Mr. Rodney Gonsalves
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1999-11-18
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Contact Information
5301 Stevens Creek Boulevard, Santa Clara, CA, 95051, United States
800-227-9770
www.agilent.com
Market Cap
$39.02B
P/E (TTM)
29.9
36.6
Dividend Yield
0.7%
52W High
$160.27
52W Low
$96.43
52W Range
65%
Rank25Top 8.6%
6.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q4 2025 Data

Revenue

$1.86B+9.41%
4-Quarter Trend

EPS

$1.53+24.39%
4-Quarter Trend

FCF

$452.00M+16.50%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Total Revenue Increased 6% Nine months revenue reached $5.09B, up 6% compared to prior year; growth across all segments noted.
Life Sciences Segment Leads Growth Life Sciences segment revenue grew 14% for the quarter and 9% for nine months, driven by BIOVECTRA.
Operating Cash Flow Strong Net cash provided by operating activities totaled $1.01B for nine months, despite a decrease from 2024.
Stock Repurchases Continue Repurchased 2.734M shares for $340M during nine months ended July 31, 2025 under 2023 plan.

Risk Factors

Net Income Declined 7% Nine months net income fell to $869M from $938M last year; diluted EPS decreased to $3.05.
Gross Margin Compression Noted Total gross margin decreased 2 percentage points to 52.2% for nine months due to tariffs and mix.
Tariff Impact on Costs Recent tariff changes adversely impacted cost of revenue in Q3; mitigation expected in fiscal year 2026.
Limited Market Visibility Quarterly results highly dependent on order timing, which is difficult to forecast; customer capital budgets constrained.

Outlook

FY2025 Restructuring Completion FY25 Plan expected to substantially complete restructuring activities by second quarter fiscal year 2026.
Capital Spending Planned Expect total capital expenditures for the current year to be approximately $400M, focused on manufacturing expansion.
Focus on Differentiated Solutions Primary focus remains enhancing customer experience and delivering differentiated product solutions for long-term growth.
FY2025 Plan Cost Savings FY25 Plan expected to yield $75M to $80M in annual cost of sales and operating expense reduction.

Peer Comparison

Revenue (TTM)

Cardinal Health, Inc.CAH
$234.31B
+4.5%
Takeda Pharmaceutical Company LimitedTAK
$29.67B
-2.8%
Haleon plcHLN
$21.43B
+46.9%

Gross Margin (Latest Quarter)

Edwards Lifesciences CorporationEW
77.9%
-2.7pp
Takeda Pharmaceutical Company LimitedTAK
65.8%
-0.6pp
Haleon plcHLN
64.5%
-0.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
IDXX$54.48B53.267.8%32.9%
EW$50.61B36.913.4%5.3%
TAK$49.28B55.31.9%32.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.4%
Moderate Growth
4Q Net Income CAGR
10.9%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 25, 2026
|
EPS:$1.37
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Jul 31, 2025|Filed: Aug 29, 2025|
    Revenue: $1.74B+10.1%
    |
    EPS: $1.18+21.6%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Apr 30, 2025|Filed: Jun 2, 2025|
    Revenue: $1.67B+6.0%
    |
    EPS: $0.75-28.6%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Jan 31, 2025|Filed: Mar 3, 2025|
    Revenue: $1.68B+1.4%
    |
    EPS: $1.12-5.9%
    Miss
  • Form 10-K - FY 2024

    Period End: Oct 31, 2024|Filed: Dec 20, 2024|
    Revenue: $6.51B-4.7%
    |
    EPS: $4.44+5.2%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Jul 31, 2024|Filed: Aug 30, 2024|
    Revenue: $1.58B-5.6%
    |
    EPS: $0.97+155.3%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Apr 30, 2024|Filed: Jun 3, 2024|
    Revenue: $1.57B-8.4%
    |
    EPS: $1.05+2.9%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Jan 31, 2024|Filed: Mar 5, 2024|
    Revenue: $1.66B-5.6%
    |
    EPS: $1.19+0.0%
    Meet
  • Form 10-K - FY 2023

    Period End: Oct 31, 2023|Filed: Dec 20, 2023|
    Revenue: $6.83B-0.2%
    |
    EPS: $4.22+0.7%
    Beat